Dexamethasone turns tumor antigen-presenting cells into tolerogenic dendritic cells with T cell inhibitory functions

• Published in: Immunobiology (1979) Vol. 224; no. 5; pp. 697 - 705
• Main Authors: Falcón-Beas, Cristián, Tittarelli, Andrés, Mora-Bau, Gabriela, Tempio, Fabián, Pérez, Claudio, Hevia, Daniel, Behrens, Carolina, Flores, Iván, Falcón-Beas, Felipe, Garrido, Paola, Ascui, Gabriel, Pereda, Cristián, González, Fermín E., Salazar-Onfray, Flavio, López, Mercedes N.
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier GmbH 01.09.2019
• Subjects: Animals; Antigen-Presenting Cells - drug effects; Antigen-Presenting Cells - immunology; Antigen-Presenting Cells - metabolism; Antigens, Neoplasm - immunology; Cytokines - metabolism; Dendritic cells; Dendritic Cells - immunology; Dendritic Cells - metabolism; Dexamethasone; Dexamethasone - pharmacology; Humans; Immune Tolerance; Immunomodulation; Immunophenotyping; Lymphocyte Activation - immunology; Lymphocytes, Tumor-Infiltrating - drug effects; Lymphocytes, Tumor-Infiltrating - immunology; Lymphocytes, Tumor-Infiltrating - metabolism; Melanoma; Mice; Phenotype; Regulatory T cells; T-Lymphocyte Subsets - immunology; T-Lymphocyte Subsets - metabolism; T-Lymphocytes - immunology; T-Lymphocytes - metabolism; Tolerance; Tolerance; Dexamethasone; Dendritic cells; Regulatory T cells; Melanoma

Dendritic cells (DCs) are usually immunogenic, but they are also capable of inducing tolerance under anti-inflammatory conditions. Immunotherapy based on autologous DCs loaded with an allogeneic melanoma cell lysate (TRIMEL/DCs) induces immunological responses and increases melanoma patient survival...